Equillium, Inc. Common Stock, also called Equillium, is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Read More Its initial product candidate, EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.